Global (United States, European Union and China) Q Fever

Q Fever Comprehensive Study by Type (Acute Q Fever, Chronic Q Fever), Treatment (Medicines (Doxycycline), Vaccination), End-users (Hospitals & Clinics, Diagnostic Centers, Surgical Centers), Diagnosis (Immunofluorescence assay (IFA), Polymerase chain reaction (PCR)) Players and Region - Global Market Outlook to 2026

Q Fever Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Q Fever?
Q fever is a bacterial infection caused by the bacterium Coxiella burnetii. These bacteria are commonly found in cattle, sheep and goats around the world. It is transmitted to humans by these animals through their urine, feces, milk and birthing products. This disease causes a sudden onset of fever, headache, malaise, and interstitial pneumonitis. Its symptoms involved high fever, up to 105 F, severe headache, fatigue, chills, cough, nausea, vomiting, diarrhea and sensitivity to light.

The market study is broken down by Type (Acute Q Fever and Chronic Q Fever) and major geographies with country level break-up.

Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Q Fever market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sanofi S.A.(France), Yashica Pharmaceuticals Private Limited (India), Merck & Co. (United States), Atox Bio (Israel), Teva Pharmaceutical Industries (Israel), Basilea Pharmaceutica Ltd. (Switzerland), MELINTA THERAPEUTICS, INC. (United States), Pfizer (United States), Cipla Inc. (India) and Johnson & Johnson Services, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Q Fever market by Type, Application and Region.

On the basis of geography, the market of Q Fever has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Medicines (Doxycycline) will boost the Q Fever market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals & Clinics will boost the Q Fever market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Immunofluorescence assay (IFA) will boost the Q Fever market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
Recently, Melinta Therapeutics, Inc., a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, has announced that Melinta and The Medicines Company have entered into an agreement pursuant to which Melinta will acquire the infectious disease business from The Medicines Company.



Market Trend
  • Growing Acceptance of Preventive Healthcare

Market Drivers
  • Serious Complications Associated with Q Fever
  • Increased Population of Sheep, Cattle and Goat
  • Increased Number of Diseases Caused by the Animals

Opportunities
  • Growth in the Q Fever Hospitalization Rate
  • Growing Healthcare Industry

Restraints
  • Side Effects Associated with Medications

Challenges
  • Lack of Healthcare Infrastructure in Some Regions


Key Target Audience
Q Fever Treatment Providers, Distributors, Government Bodies and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Acute Q Fever
  • Chronic Q Fever
By Treatment
  • Medicines (Doxycycline)
  • Vaccination

By End-users
  • Hospitals & Clinics
  • Diagnostic Centers
  • Surgical Centers

By Diagnosis
  • Immunofluorescence assay (IFA)
  • Polymerase chain reaction (PCR)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Serious Complications Associated with Q Fever
      • 3.2.2. Increased Population of Sheep, Cattle and Goat
      • 3.2.3. Increased Number of Diseases Caused by the Animals
    • 3.3. Market Challenges
      • 3.3.1. Lack of Healthcare Infrastructure in Some Regions
    • 3.4. Market Trends
      • 3.4.1. Growing Acceptance of Preventive Healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Q Fever, by Type, Treatment, End-users, Diagnosis and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Q Fever (Value)
      • 5.2.1. Global Q Fever by: Type (Value)
        • 5.2.1.1. Acute Q Fever
        • 5.2.1.2. Chronic Q Fever
      • 5.2.2. Global Q Fever by: Treatment (Value)
        • 5.2.2.1. Medicines (Doxycycline)
        • 5.2.2.2. Vaccination
      • 5.2.3. Global Q Fever by: End-users (Value)
        • 5.2.3.1. Hospitals & Clinics
        • 5.2.3.2. Diagnostic Centers
        • 5.2.3.3. Surgical Centers
      • 5.2.4. Global Q Fever by: Diagnosis (Value)
        • 5.2.4.1. Immunofluorescence assay (IFA)
        • 5.2.4.2. Polymerase chain reaction (PCR)
      • 5.2.5. Global Q Fever Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Q Fever: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi S.A.(France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Yashica Pharmaceuticals Private Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Atox Bio (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Basilea Pharmaceutica Ltd. (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MELINTA THERAPEUTICS, INC. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cipla Inc. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson Services, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Q Fever Sale, by Type, Treatment, End-users, Diagnosis and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Q Fever (Value)
      • 7.2.1. Global Q Fever by: Type (Value)
        • 7.2.1.1. Acute Q Fever
        • 7.2.1.2. Chronic Q Fever
      • 7.2.2. Global Q Fever by: Treatment (Value)
        • 7.2.2.1. Medicines (Doxycycline)
        • 7.2.2.2. Vaccination
      • 7.2.3. Global Q Fever by: End-users (Value)
        • 7.2.3.1. Hospitals & Clinics
        • 7.2.3.2. Diagnostic Centers
        • 7.2.3.3. Surgical Centers
      • 7.2.4. Global Q Fever by: Diagnosis (Value)
        • 7.2.4.1. Immunofluorescence assay (IFA)
        • 7.2.4.2. Polymerase chain reaction (PCR)
      • 7.2.5. Global Q Fever Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Q Fever: by Type(USD Million)
  • Table 2. Q Fever Acute Q Fever , by Region USD Million (2015-2020)
  • Table 3. Q Fever Chronic Q Fever , by Region USD Million (2015-2020)
  • Table 4. Q Fever: by Treatment(USD Million)
  • Table 5. Q Fever Medicines (Doxycycline) , by Region USD Million (2015-2020)
  • Table 6. Q Fever Vaccination , by Region USD Million (2015-2020)
  • Table 7. Q Fever: by End-users(USD Million)
  • Table 8. Q Fever Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 9. Q Fever Diagnostic Centers , by Region USD Million (2015-2020)
  • Table 10. Q Fever Surgical Centers , by Region USD Million (2015-2020)
  • Table 11. Q Fever: by Diagnosis(USD Million)
  • Table 12. Q Fever Immunofluorescence assay (IFA) , by Region USD Million (2015-2020)
  • Table 13. Q Fever Polymerase chain reaction (PCR) , by Region USD Million (2015-2020)
  • Table 14. South America Q Fever, by Country USD Million (2015-2020)
  • Table 15. South America Q Fever, by Type USD Million (2015-2020)
  • Table 16. South America Q Fever, by Treatment USD Million (2015-2020)
  • Table 17. South America Q Fever, by End-users USD Million (2015-2020)
  • Table 18. South America Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 19. Brazil Q Fever, by Type USD Million (2015-2020)
  • Table 20. Brazil Q Fever, by Treatment USD Million (2015-2020)
  • Table 21. Brazil Q Fever, by End-users USD Million (2015-2020)
  • Table 22. Brazil Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 23. Argentina Q Fever, by Type USD Million (2015-2020)
  • Table 24. Argentina Q Fever, by Treatment USD Million (2015-2020)
  • Table 25. Argentina Q Fever, by End-users USD Million (2015-2020)
  • Table 26. Argentina Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 27. Rest of South America Q Fever, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Q Fever, by Treatment USD Million (2015-2020)
  • Table 29. Rest of South America Q Fever, by End-users USD Million (2015-2020)
  • Table 30. Rest of South America Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 31. Asia Pacific Q Fever, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Q Fever, by Type USD Million (2015-2020)
  • Table 33. Asia Pacific Q Fever, by Treatment USD Million (2015-2020)
  • Table 34. Asia Pacific Q Fever, by End-users USD Million (2015-2020)
  • Table 35. Asia Pacific Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 36. China Q Fever, by Type USD Million (2015-2020)
  • Table 37. China Q Fever, by Treatment USD Million (2015-2020)
  • Table 38. China Q Fever, by End-users USD Million (2015-2020)
  • Table 39. China Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 40. Japan Q Fever, by Type USD Million (2015-2020)
  • Table 41. Japan Q Fever, by Treatment USD Million (2015-2020)
  • Table 42. Japan Q Fever, by End-users USD Million (2015-2020)
  • Table 43. Japan Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 44. India Q Fever, by Type USD Million (2015-2020)
  • Table 45. India Q Fever, by Treatment USD Million (2015-2020)
  • Table 46. India Q Fever, by End-users USD Million (2015-2020)
  • Table 47. India Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 48. South Korea Q Fever, by Type USD Million (2015-2020)
  • Table 49. South Korea Q Fever, by Treatment USD Million (2015-2020)
  • Table 50. South Korea Q Fever, by End-users USD Million (2015-2020)
  • Table 51. South Korea Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 52. Taiwan Q Fever, by Type USD Million (2015-2020)
  • Table 53. Taiwan Q Fever, by Treatment USD Million (2015-2020)
  • Table 54. Taiwan Q Fever, by End-users USD Million (2015-2020)
  • Table 55. Taiwan Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 56. Australia Q Fever, by Type USD Million (2015-2020)
  • Table 57. Australia Q Fever, by Treatment USD Million (2015-2020)
  • Table 58. Australia Q Fever, by End-users USD Million (2015-2020)
  • Table 59. Australia Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Q Fever, by Type USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Q Fever, by Treatment USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Q Fever, by End-users USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 64. Europe Q Fever, by Country USD Million (2015-2020)
  • Table 65. Europe Q Fever, by Type USD Million (2015-2020)
  • Table 66. Europe Q Fever, by Treatment USD Million (2015-2020)
  • Table 67. Europe Q Fever, by End-users USD Million (2015-2020)
  • Table 68. Europe Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 69. Germany Q Fever, by Type USD Million (2015-2020)
  • Table 70. Germany Q Fever, by Treatment USD Million (2015-2020)
  • Table 71. Germany Q Fever, by End-users USD Million (2015-2020)
  • Table 72. Germany Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 73. France Q Fever, by Type USD Million (2015-2020)
  • Table 74. France Q Fever, by Treatment USD Million (2015-2020)
  • Table 75. France Q Fever, by End-users USD Million (2015-2020)
  • Table 76. France Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 77. Italy Q Fever, by Type USD Million (2015-2020)
  • Table 78. Italy Q Fever, by Treatment USD Million (2015-2020)
  • Table 79. Italy Q Fever, by End-users USD Million (2015-2020)
  • Table 80. Italy Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 81. United Kingdom Q Fever, by Type USD Million (2015-2020)
  • Table 82. United Kingdom Q Fever, by Treatment USD Million (2015-2020)
  • Table 83. United Kingdom Q Fever, by End-users USD Million (2015-2020)
  • Table 84. United Kingdom Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 85. Netherlands Q Fever, by Type USD Million (2015-2020)
  • Table 86. Netherlands Q Fever, by Treatment USD Million (2015-2020)
  • Table 87. Netherlands Q Fever, by End-users USD Million (2015-2020)
  • Table 88. Netherlands Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 89. Rest of Europe Q Fever, by Type USD Million (2015-2020)
  • Table 90. Rest of Europe Q Fever, by Treatment USD Million (2015-2020)
  • Table 91. Rest of Europe Q Fever, by End-users USD Million (2015-2020)
  • Table 92. Rest of Europe Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 93. MEA Q Fever, by Country USD Million (2015-2020)
  • Table 94. MEA Q Fever, by Type USD Million (2015-2020)
  • Table 95. MEA Q Fever, by Treatment USD Million (2015-2020)
  • Table 96. MEA Q Fever, by End-users USD Million (2015-2020)
  • Table 97. MEA Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 98. Middle East Q Fever, by Type USD Million (2015-2020)
  • Table 99. Middle East Q Fever, by Treatment USD Million (2015-2020)
  • Table 100. Middle East Q Fever, by End-users USD Million (2015-2020)
  • Table 101. Middle East Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 102. Africa Q Fever, by Type USD Million (2015-2020)
  • Table 103. Africa Q Fever, by Treatment USD Million (2015-2020)
  • Table 104. Africa Q Fever, by End-users USD Million (2015-2020)
  • Table 105. Africa Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 106. North America Q Fever, by Country USD Million (2015-2020)
  • Table 107. North America Q Fever, by Type USD Million (2015-2020)
  • Table 108. North America Q Fever, by Treatment USD Million (2015-2020)
  • Table 109. North America Q Fever, by End-users USD Million (2015-2020)
  • Table 110. North America Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 111. United States Q Fever, by Type USD Million (2015-2020)
  • Table 112. United States Q Fever, by Treatment USD Million (2015-2020)
  • Table 113. United States Q Fever, by End-users USD Million (2015-2020)
  • Table 114. United States Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 115. Canada Q Fever, by Type USD Million (2015-2020)
  • Table 116. Canada Q Fever, by Treatment USD Million (2015-2020)
  • Table 117. Canada Q Fever, by End-users USD Million (2015-2020)
  • Table 118. Canada Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 119. Mexico Q Fever, by Type USD Million (2015-2020)
  • Table 120. Mexico Q Fever, by Treatment USD Million (2015-2020)
  • Table 121. Mexico Q Fever, by End-users USD Million (2015-2020)
  • Table 122. Mexico Q Fever, by Diagnosis USD Million (2015-2020)
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Q Fever: by Type(USD Million)
  • Table 134. Q Fever Acute Q Fever , by Region USD Million (2021-2026)
  • Table 135. Q Fever Chronic Q Fever , by Region USD Million (2021-2026)
  • Table 136. Q Fever: by Treatment(USD Million)
  • Table 137. Q Fever Medicines (Doxycycline) , by Region USD Million (2021-2026)
  • Table 138. Q Fever Vaccination , by Region USD Million (2021-2026)
  • Table 139. Q Fever: by End-users(USD Million)
  • Table 140. Q Fever Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 141. Q Fever Diagnostic Centers , by Region USD Million (2021-2026)
  • Table 142. Q Fever Surgical Centers , by Region USD Million (2021-2026)
  • Table 143. Q Fever: by Diagnosis(USD Million)
  • Table 144. Q Fever Immunofluorescence assay (IFA) , by Region USD Million (2021-2026)
  • Table 145. Q Fever Polymerase chain reaction (PCR) , by Region USD Million (2021-2026)
  • Table 146. South America Q Fever, by Country USD Million (2021-2026)
  • Table 147. South America Q Fever, by Type USD Million (2021-2026)
  • Table 148. South America Q Fever, by Treatment USD Million (2021-2026)
  • Table 149. South America Q Fever, by End-users USD Million (2021-2026)
  • Table 150. South America Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 151. Brazil Q Fever, by Type USD Million (2021-2026)
  • Table 152. Brazil Q Fever, by Treatment USD Million (2021-2026)
  • Table 153. Brazil Q Fever, by End-users USD Million (2021-2026)
  • Table 154. Brazil Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 155. Argentina Q Fever, by Type USD Million (2021-2026)
  • Table 156. Argentina Q Fever, by Treatment USD Million (2021-2026)
  • Table 157. Argentina Q Fever, by End-users USD Million (2021-2026)
  • Table 158. Argentina Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 159. Rest of South America Q Fever, by Type USD Million (2021-2026)
  • Table 160. Rest of South America Q Fever, by Treatment USD Million (2021-2026)
  • Table 161. Rest of South America Q Fever, by End-users USD Million (2021-2026)
  • Table 162. Rest of South America Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 163. Asia Pacific Q Fever, by Country USD Million (2021-2026)
  • Table 164. Asia Pacific Q Fever, by Type USD Million (2021-2026)
  • Table 165. Asia Pacific Q Fever, by Treatment USD Million (2021-2026)
  • Table 166. Asia Pacific Q Fever, by End-users USD Million (2021-2026)
  • Table 167. Asia Pacific Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 168. China Q Fever, by Type USD Million (2021-2026)
  • Table 169. China Q Fever, by Treatment USD Million (2021-2026)
  • Table 170. China Q Fever, by End-users USD Million (2021-2026)
  • Table 171. China Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 172. Japan Q Fever, by Type USD Million (2021-2026)
  • Table 173. Japan Q Fever, by Treatment USD Million (2021-2026)
  • Table 174. Japan Q Fever, by End-users USD Million (2021-2026)
  • Table 175. Japan Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 176. India Q Fever, by Type USD Million (2021-2026)
  • Table 177. India Q Fever, by Treatment USD Million (2021-2026)
  • Table 178. India Q Fever, by End-users USD Million (2021-2026)
  • Table 179. India Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 180. South Korea Q Fever, by Type USD Million (2021-2026)
  • Table 181. South Korea Q Fever, by Treatment USD Million (2021-2026)
  • Table 182. South Korea Q Fever, by End-users USD Million (2021-2026)
  • Table 183. South Korea Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 184. Taiwan Q Fever, by Type USD Million (2021-2026)
  • Table 185. Taiwan Q Fever, by Treatment USD Million (2021-2026)
  • Table 186. Taiwan Q Fever, by End-users USD Million (2021-2026)
  • Table 187. Taiwan Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 188. Australia Q Fever, by Type USD Million (2021-2026)
  • Table 189. Australia Q Fever, by Treatment USD Million (2021-2026)
  • Table 190. Australia Q Fever, by End-users USD Million (2021-2026)
  • Table 191. Australia Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 192. Rest of Asia-Pacific Q Fever, by Type USD Million (2021-2026)
  • Table 193. Rest of Asia-Pacific Q Fever, by Treatment USD Million (2021-2026)
  • Table 194. Rest of Asia-Pacific Q Fever, by End-users USD Million (2021-2026)
  • Table 195. Rest of Asia-Pacific Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 196. Europe Q Fever, by Country USD Million (2021-2026)
  • Table 197. Europe Q Fever, by Type USD Million (2021-2026)
  • Table 198. Europe Q Fever, by Treatment USD Million (2021-2026)
  • Table 199. Europe Q Fever, by End-users USD Million (2021-2026)
  • Table 200. Europe Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 201. Germany Q Fever, by Type USD Million (2021-2026)
  • Table 202. Germany Q Fever, by Treatment USD Million (2021-2026)
  • Table 203. Germany Q Fever, by End-users USD Million (2021-2026)
  • Table 204. Germany Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 205. France Q Fever, by Type USD Million (2021-2026)
  • Table 206. France Q Fever, by Treatment USD Million (2021-2026)
  • Table 207. France Q Fever, by End-users USD Million (2021-2026)
  • Table 208. France Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 209. Italy Q Fever, by Type USD Million (2021-2026)
  • Table 210. Italy Q Fever, by Treatment USD Million (2021-2026)
  • Table 211. Italy Q Fever, by End-users USD Million (2021-2026)
  • Table 212. Italy Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 213. United Kingdom Q Fever, by Type USD Million (2021-2026)
  • Table 214. United Kingdom Q Fever, by Treatment USD Million (2021-2026)
  • Table 215. United Kingdom Q Fever, by End-users USD Million (2021-2026)
  • Table 216. United Kingdom Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 217. Netherlands Q Fever, by Type USD Million (2021-2026)
  • Table 218. Netherlands Q Fever, by Treatment USD Million (2021-2026)
  • Table 219. Netherlands Q Fever, by End-users USD Million (2021-2026)
  • Table 220. Netherlands Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 221. Rest of Europe Q Fever, by Type USD Million (2021-2026)
  • Table 222. Rest of Europe Q Fever, by Treatment USD Million (2021-2026)
  • Table 223. Rest of Europe Q Fever, by End-users USD Million (2021-2026)
  • Table 224. Rest of Europe Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 225. MEA Q Fever, by Country USD Million (2021-2026)
  • Table 226. MEA Q Fever, by Type USD Million (2021-2026)
  • Table 227. MEA Q Fever, by Treatment USD Million (2021-2026)
  • Table 228. MEA Q Fever, by End-users USD Million (2021-2026)
  • Table 229. MEA Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 230. Middle East Q Fever, by Type USD Million (2021-2026)
  • Table 231. Middle East Q Fever, by Treatment USD Million (2021-2026)
  • Table 232. Middle East Q Fever, by End-users USD Million (2021-2026)
  • Table 233. Middle East Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 234. Africa Q Fever, by Type USD Million (2021-2026)
  • Table 235. Africa Q Fever, by Treatment USD Million (2021-2026)
  • Table 236. Africa Q Fever, by End-users USD Million (2021-2026)
  • Table 237. Africa Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 238. North America Q Fever, by Country USD Million (2021-2026)
  • Table 239. North America Q Fever, by Type USD Million (2021-2026)
  • Table 240. North America Q Fever, by Treatment USD Million (2021-2026)
  • Table 241. North America Q Fever, by End-users USD Million (2021-2026)
  • Table 242. North America Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 243. United States Q Fever, by Type USD Million (2021-2026)
  • Table 244. United States Q Fever, by Treatment USD Million (2021-2026)
  • Table 245. United States Q Fever, by End-users USD Million (2021-2026)
  • Table 246. United States Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 247. Canada Q Fever, by Type USD Million (2021-2026)
  • Table 248. Canada Q Fever, by Treatment USD Million (2021-2026)
  • Table 249. Canada Q Fever, by End-users USD Million (2021-2026)
  • Table 250. Canada Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 251. Mexico Q Fever, by Type USD Million (2021-2026)
  • Table 252. Mexico Q Fever, by Treatment USD Million (2021-2026)
  • Table 253. Mexico Q Fever, by End-users USD Million (2021-2026)
  • Table 254. Mexico Q Fever, by Diagnosis USD Million (2021-2026)
  • Table 255. Research Programs/Design for This Report
  • Table 256. Key Data Information from Secondary Sources
  • Table 257. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Q Fever: by Type USD Million (2015-2020)
  • Figure 5. Global Q Fever: by Treatment USD Million (2015-2020)
  • Figure 6. Global Q Fever: by End-users USD Million (2015-2020)
  • Figure 7. Global Q Fever: by Diagnosis USD Million (2015-2020)
  • Figure 8. South America Q Fever Share (%), by Country
  • Figure 9. Asia Pacific Q Fever Share (%), by Country
  • Figure 10. Europe Q Fever Share (%), by Country
  • Figure 11. MEA Q Fever Share (%), by Country
  • Figure 12. North America Q Fever Share (%), by Country
  • Figure 13. Global Q Fever share by Players 2020 (%)
  • Figure 14. Global Q Fever share by Players (Top 3) 2020(%)
  • Figure 15. Global Q Fever share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Sanofi S.A.(France) Revenue, Net Income and Gross profit
  • Figure 18. Sanofi S.A.(France) Revenue: by Geography 2020
  • Figure 19. Yashica Pharmaceuticals Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 20. Yashica Pharmaceuticals Private Limited (India) Revenue: by Geography 2020
  • Figure 21. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 23. Atox Bio (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Atox Bio (Israel) Revenue: by Geography 2020
  • Figure 25. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 26. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2020
  • Figure 27. Basilea Pharmaceutica Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Basilea Pharmaceutica Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 29. MELINTA THERAPEUTICS, INC. (United States) Revenue, Net Income and Gross profit
  • Figure 30. MELINTA THERAPEUTICS, INC. (United States) Revenue: by Geography 2020
  • Figure 31. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer (United States) Revenue: by Geography 2020
  • Figure 33. Cipla Inc. (India) Revenue, Net Income and Gross profit
  • Figure 34. Cipla Inc. (India) Revenue: by Geography 2020
  • Figure 35. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Global Q Fever: by Type USD Million (2021-2026)
  • Figure 38. Global Q Fever: by Treatment USD Million (2021-2026)
  • Figure 39. Global Q Fever: by End-users USD Million (2021-2026)
  • Figure 40. Global Q Fever: by Diagnosis USD Million (2021-2026)
  • Figure 41. South America Q Fever Share (%), by Country
  • Figure 42. Asia Pacific Q Fever Share (%), by Country
  • Figure 43. Europe Q Fever Share (%), by Country
  • Figure 44. MEA Q Fever Share (%), by Country
  • Figure 45. North America Q Fever Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sanofi S.A.(France)
  • Yashica Pharmaceuticals Private Limited (India)
  • Merck & Co. (United States)
  • Atox Bio (Israel)
  • Teva Pharmaceutical Industries (Israel)
  • Basilea Pharmaceutica Ltd. (Switzerland)
  • MELINTA THERAPEUTICS, INC. (United States)
  • Pfizer (United States)
  • Cipla Inc. (India)
  • Johnson & Johnson Services, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2022 230 Pages 79 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Q Fever Quantitative research analysis
Global (United States, European Union and China) Q Fever Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sanofi S.A.(France), Yashica Pharmaceuticals Private Limited (India), Merck & Co. (United States), Atox Bio (Israel), Teva Pharmaceutical Industries (Israel), Basilea Pharmaceutica Ltd. (Switzerland), MELINTA THERAPEUTICS, INC. (United States), Pfizer (United States), Cipla Inc. (India) and Johnson & Johnson Services, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates Q Fever Market to reach USD Million by 2026.

Know More About Global (United States, European Union and China) Q Fever Report?

Have a Query? Click Here

Other Related Reports

Multiple Myeloma Treatment Comprehensive Study by Application (Hospitals, Specialty Clinics, Cancer Treatment and Rehabilitation Centers, Research Organization, Laboratories), Route of Administration...
$ 3800
Mumps Virus Testing Comprehensive Study by Type (Cell Culture/Immunofluorescence, Semi-Quantitative Enzyme-Linked Immunosorbent Assay, Semi-Quantitative Chemiluminescent Immunoassay, Qualitative Real...
$ 3450
Colon Cancer Comprehensive Study by Type (Surgery, Chemotherapy, Radiation), Application (Hospitals, Ambulatory Surgical Centers, Others), Testing Techniques (Macroscopy, Microscopy, Immunochemistry,...
$ 3750
Dysphagia Management Comprehensive Study by Type (High (Oropharangeal) Dysphagia, Low (Esophageal) Dysphagia), Application (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Specialty Clinics) Pla...
$ 3500
Combination Antibody Therapy Comprehensive Study by Type (Chemotherapy/Antibody, Antibody/Antibody, Conjugated Antibodies, Bispecific Antibodies), Application (Lung Cancer, Blood Cancer (Lymphoma, Le...
$ 3650
Carcinoid Syndrome Diarrhea Treatment Comprehensive Study by End User (Hospitals and Clinics, Cancer Research Institutes, Others), Treatment (Chemotherapy, Oral Therapy, Somatostatin Analog (SSA) Th...
$ 3500